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The activity of the p53 tumor suppressor protein is regulated, at least in part, through the stability of the protein. p53
degradation in normal cells is controlled by ubiquitin-dependent proteolysis, and activation of p53 following DNA damage
is associated with an increase in the stability of the protein. The human papillomavirus-encoded E6 protein abrogates p53
function by targeting it for rapid degradation, also through the ubiquitin pathway. Although the p53 protein is ubiquitinated
following interaction with E6, we show here that none of the lysine residues within p53 are specifically required for E6-
targeted degradation. Mutation of lysine residues within the C-terminus of p53 resulted in resistance to E6-mediated
degradation in vitro, although the ability of the two proteins to form a complex was not affected. The same mutant was
efficiently targeted for degradation in cells, however, illustrating a lack of correlation between the in vitro and the in vivo
assays. q 1996 Academic Press, Inc.
INTRODUCTION nover et al., 1991), although the factors regulating sensi-
tivity of p53 to degradation, either before or after DNA
The p53 tumor suppressor protein plays an important
damage, are not well understood.
role in mediating the cellular response to DNA damage
p53 function is lost in most cancers by point mutation
(Lane, 1992). Following exposure to genotoxic agents,
within the p53 gene itself (Greenblatt et al., 1994). How-
activation of p53 prevents replication of damaged DNA
ever, in cervical cancers, which are almost all associated
by either instituting cell cycle arrest or by targeting the
with infection by human papillomavirus (zur Hausen,
damaged cell for apoptosis (Oren, 1994). Loss of normal
1991), interaction of the virally encoded E6 protein and
p53 function is detected in most human tumors and inac-
p53 abrogates the normal function of the tumor suppres-
tivation of p53 function has been shown to result in en-
sor protein. The E6 protein forms a complex with p53
hanced genomic instability (Smith and Fornace, 1995).
(Werness et al., 1990) and another cellular protein called
p53 is therefore thought to regulate an important check-
E6AP (Huibregtse et al., 1991), with the resultant rapid
point to ensure fidelity of DNA replication and prevent
degradation of p53 (Scheffner et al., 1990). E6-expressing
the accumulation of potentially oncogenic genomic alter-
cells therefore express very low levels of p53 and these
ations. Several studies have shown that double-strand
protein levels are not elevated following DNA damage
DNA breaks can signal the activation of p53 (Di Leonardo
(Foster et al., 1994; Kessis et al., 1993). Interestingly,
et al., 1994; Nelson and Kastan, 1994), and following
E6-targeted degradation of p53 also occurs through the
detection of such damage p53 protein levels, which are
ubiquitin pathway, the complex between E6 and E6AP
generally low in normal cells, start to rise (Maltzman and
functioning as an E3 ubiquitin ligase (Scheffner et al.,
Czyzyk, 1984). One of the mechanisms by which this
1993). E2 ubiquitin-conjugating enzymes which partici-
increase in p53 protein is achieved is through enhance-
pate in E6-mediated p53 degradation have also been
ment of protein stability (Fritsche et al., 1993; Kastan et
identified (Ciechanover et al., 1994; Scheffner et al.,
al., 1991), although increased p53 transcription in re-
1994), although their contribution to the normal, E6-inde-
sponse to genotoxic stress has also been reported (Sun
pendent, regulation of p53 proteolysis has not been es-
et al., 1995). p53 is normally degraded through a ubiqui-
tablished.
tin-dependent pathway (Chowdary et al., 1994; Ciecha-
Ubiquitin-dependent degradation is clearly an im-
portant mechanism for regulating p53 function and since
1 The U.S. Government’s right to retain a nonexclusive royalty-free an essential step in this proteolytic pathway is the cova-
license in and to the copyright covering this paper, for governmental
lent attachment of multiple ubiquitin molecules to lysinepurposes, is acknowledged.
residues within the protein (Ciechanover, 1994), we2 To whom correspondence and reprint requests should be ad-
dressed. Fax: (301) 846-6666; E-mail: vousden@ncifcrf.gov. sought to determine whether any lysine within p53 was
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critical for sensitivity to E6-mediated degradation. Our 10 min at room temperature with indicated p53-specific
monoclonal antibodies, then carrier DNA, 21 DNA bind-results showed that no specific lysine residue within p53
is necessary for E6-directed degradation and, further- ing buffer (to final concentration of 20% glycerol, 25 mM
HEPES, pH 7.6, 50 nM KCl, 1 mM DTT, 1 mg/ml BSA,more, we demonstrate that resistance to E6-mediated
degradation in the in vitro assay systems commonly used 0.1% Triton X-100), and 2–4 ng 32P-labeled probe were
added and incubated for a further 30 min on ice. Reac-to study this pathway does not necessarily reflect an
insensitivity to E6 in vivo. tions were run on native 4% polyacrylamide, 0.51 TBE,
0.1% Triton X-100 gels at 200 V at 47 for 1–3 hr. For
competition 200 ng of unlabeled oligonucleotide wasMATERIALS AND METHODS
added with the antibody.
p53 mutagenesis
Transcriptional activationp53 lysine mutants were constructed in the wild-type
human p53 sequences (Matlashewski et al., 1987) by p53 null fibroblasts were maintained in DMEM with
oligonucleotide-directed mutagenesis as previously de- 10% fetal calf serum and transfected using calcium phos-
scribed (Marston et al., 1994). In each case the lysine phate coprecipitation as previously described (Crook et
residue was mutated to an isoleucine. Mutants were al., 1991a). p53 sequences were expressed from the
identified by sequencing and then subcloned into SV40 promoter in the plasmid pJ3V and E6 sequences
pGEM4Z (Promega) for in vitro transcription and pJ3V were expressed from the CMV promoter in the plasmid
(Wilkinson et al., 1988) for eukaryotic expression in trans- pCB6/. Reporter plasmids used to detect p53-depen-
fection assays. dent transcriptional activation were pG13-luc (El-Deiry et
al., 1993) and pGL2NA(mdm2)-luc (Juven et al., 1993).E6 binding and E6-mediated degradation assays
Transfected cells were harvested 48–60 hr after trans-
p53 and E6 proteins were transcribed and translated in fection and lysates were prepared for the analysis of
rabbit reticulocyte lysates (RRL) as previously described luciferase activity as previously described (Lam and Was-
(Marston et al., 1994). For degradation assays [ 35S]- ton, 1993). Aliquots of the same lysates were also ana-
methionine-labeled p53 proteins were mixed with E6 in lyzed by Western blotting using the anti-p53 monoclonal
25 mM Tris (pH 7.5), 100 mM NaCl, and 3 mM dithiothrei- antibody DO-1 (Vojtesek et al., 1992).
tol (DTT) for up to 3 hr at room temperature. Aliquots
were removed at the indicated time points and immedi- RESULTS
ately boiled in SDS sample buffer. The samples were
In vitro interactions of p53 lysine mutants with E6then analyzed by 12% PAGE and autoradiography. E6–
p53 binding assays were carried out using unlabeled To assess the contribution of specific lysine residues
p53 and 35S-labeled E6. The proteins were incubated in within the p53 protein to the degradation of the protein,
LSAB (100 mM NaCl, 0.1 M Tris, pH 8, 1% NP-40) at 47 each lysine residue was mutated to isoleucine either
for 2 hr. The complexes were then immunoprecipitated independently or in groups as shown in Fig. 1. The ability
using the p53-specific monoclonal antibody PAb1801 of these p53 mutants to interact with HPV16 E6 was
(Banks et al., 1986) and analyzed by 15% PAGE and auto- tested in vitro, following translation of both p53 and E6
radiography. In each case an aliquot of the p53 transla- in rabbit reticulocyte lysates. Incubation of E6 with p53 for
tion mixture was removed and incubated with [ 35S]- up to 3 hr demonstrated that all the p53 mutant proteins
methionine to monitor successful translation of each mu- retained sensitivity to E6-directed degradation except
tant protein. p53I381/382/386, which was only slightly reduced during
this time course (Fig. 2A). Since three lysine residuesp53 DNA-binding activity
were altered in this mutant, we tested p53 proteins in
which each of these lysines was separately mutated (Fig.The DNA-binding activity of in vitro-translated (IVT) p53
proteins was tested by electrophoresis mobility shift 2B). Independent alteration of each lysine residue
(p53I381, p53I382, p53I386) did not confer resistance toassay using a protocol modified from two previous publi-
cations (Halazonetis et al., 1993; Hupp et al., 1992). Com- E6-directed degradation (Fig. 2B), illustrating that none of
these residues is specifically the target for ubiquitinationplementary oligonucleotides encoding two consensus
p53 binding sites (El-Deiry et al., 1992) (GGTAGACAT- following the interaction with E6. This is consistent with
our previous observation that a small deletion of the C-GCCTAGACATGCCTA and GGTAGGCATGTCTAGGCA-
TGTCTA) were hybridized, end-labeled using [ 32P]dCTP terminus of p53, removing residues 370 to 393
(p53D370), does not prevent recognition and degrada-and Klenow fragment, and gel purified. Reactions were
carried out in 20-ml volumes: for each reaction, 3 ml IVT tion by E6, although a more extensive deletion to residue
327 (p53D327) abolishes this interaction (Fig. 2B). Sincep53 from a 20-ml translation in RRL was preincubated for
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FIG. 1. Representation of the human p53 protein showing the evolutionarily conserved boxes I–V, the N-terminal transactivation domain, the
central sequence-specific DNA binding domain, and the C-terminal regulatory region. The positions of the lysine mutants analyzed in this study
and the epitopes recognized by the antibodies PAb1801 and PAb421 are also shown.
the deletion in p53D370 removes all three lysine resi- Activation of DNA binding by C-terminal mutations
within p53dues in p53I381/382/386, it seems unlikely that any of
these represents a specific target for ubiquitination,
The extreme C-terminus of p53 has been identifiedwhich can clearly occur in the absence of these residues.
as an important regulatory region of the protein, withPrevious analyses of p53 mutants have demonstrated
mutations within this region affecting the sequence-spe-a good correlation between the ability of E6 to interact
cific DNA binding activity. Since the resistance to E6-with p53 and the ability to target degradation (Crook and
mediated degradation exhibited by p53I381/382/386 wasVousden, 1992; Scheffner et al., 1992b); p53 mutants
apparently not the result of loss of a critical lysine residuewhich are resistant to E6-mediated degradation have
or an inability to interact with E6, we sought to determinegenerally also lost the ability to interact with E6. As ex-
whether this mutant showed alterations in other func-pected, co-incubation of the two proteins and subse-
tions regulated by the C-terminus, such as DNA-bindingquent immunoprecipitation through p53 showed that all
activity. We therefore analyzed the in vitro translated C-p53 proteins which retain sensitivity to E6-mediated deg-
terminal p53 mutants for DNA binding by bandshift analy-radation also bind E6 (Fig. 3). The degradation-resistant
sis (Fig. 4). As shown previously, wild-type p53 DNA-deletion mutant p53D327 failed to interact with E6, as
binding function could be activated by interaction withpreviously shown. Interestingly, p53I381/382/386 re-
the monoclonal antibody PAb421, an activity which wastained the ability to interact with E6, despite showing
resistance to E6-targeted degradation. competed by the addition of excess unlabeled p53 bind-
FIG. 2. (A) Degradation of p53 proteins following incubation with HPV16 E6 in vitro. Amount of p53 remaining after 0, 1, and 3 hr of incubation
with E6 is shown for the indicated lysine mutants and wild-type p53. p53 mutants not shown were all sensitive to E6-mediated degradation. Stability
of the wild-type p53 protein over the 3-hr time course in the absence of E6 is also shown. (B) E6-directed degradation of p53 proteins carrying a
triple lysine mutation within the C-terminus (I381/382/386) or independent substitutions at each of these residues. Degradation of truncated p53
proteins lacking this C-terminal region (p53D370 and p53D327) are also shown.
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fore not possible to test the whether this mutant could
be activated for DNA binding following interaction with
this antibody. However the retention of sequence-spe-
cific transcriptional activity by this mutant (see below)
indicates that it has not lost DNA-binding activity.
FIG. 3. Association of E6 with selected p53 lysine mutants. (A) Trans-
lation of each p53 mutant demonstrating the amounts of input protein.
(B) E6 coprecipitated with each of the p53 mutants using the anti-p53
antibody PAb1801.
ing site oligonucleotide. Deletion of the C-terminal 24
amino acids in p53D370 gave rise to a p53 protein which
was constitutively activated for DNA binding in a manner
similar to that previously described for a p53 mutant lack-
ing the C-terminal 30 amino acid residues (Hupp et al.,
1992). Since this mutant has lost the C-terminal epitope
for PAb421, specificity of this complex was demonstrated
by supershifting with the antibody PAb1801, which recog-
nizes an epitope in the N-terminus of the p53 protein.
Unlike p53D370, the triple lysine mutant p53I381/382/
386 did not show a constitutive DNA-binding activity. The
point mutations within this protein also disrupted the
recognition by PAb421 (data not shown) and it was there-
FIG. 4. DNA-binding activity of in vitro-translated p53 proteins, follow- FIG. 5. Sequence-specific transcriptional transactivating activity of
the p53 mutants in p53 null mouse fibroblasts. (A) Activation of theing incubation with the anti-p53 antibodies PAb1801 and PAb421 as
indicated. Specificity of the electrophoretic mobility shift is demon- mdm2 promoter in pGL2NA(mdm2)-luc using 3 mg of each p53 plasmid.
(B) Activation of the synthetic p53-responsive promoter in pG13-luc us-strated by addition of unlabeled competitor p53 binding site oligonucle-
otide. ing 1 mg of each p53 plasmid.
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FIG. 6. Western blot of extracts from p53 null mouse fibroblasts showing levels of p53 expression following transient transfection of 0.5, 1.0, or
5.0 mg of the indicated p53 plasmids.
Transcriptional activity of p53 lysine mutants the p53 mutant p53DV, which has previously been shown
to be resistant to E6-mediated degradation in vitro (Mar-
Transfection of p53 null mouse fibroblasts showed that ston et al., 1994), remain unaffected by coexpression of
all of the p53 lysine mutants retained the ability to effi- E6 (Fig. 8B), illustrating that E6 is not modulating tran-
ciently activate transcription from both the synthetic p53- scription of the p53 sequences in these assays.
responsive promoter in the reporter plasmid pG13-luc and
the mdm2 promoter in pNALuc, with the exception of DISCUSSION
p53I132, which showed complete loss of transactivating
Analysis of p53 proteins with substitutions of the lysineactivity (Fig. 5). This residue lies within the central DNA-
residues has demonstrated that ubiquitination and deg-binding domain of p53 (Cho et al., 1994) and loss of
radation by E6 is not dependent on the presence of anysequence-specific transcriptional activity suggests that
specific lysine residue. This suggests that either morethis mutation, like many others within this region, inhibits
than one lysine residue is normally targeted or that alter-DNA binding by p53. Western blot analysis showed that
native lysines may be utilized if the normally ubiquitinatedalthough there was some variation, each of the p53 mu-
amino acid is mutated. Substitution of the lysine residuetants was expressed at levels broadly comparable to
in the DNA-binding domain in p53, in p53I132, had nothose of the wild-type protein, with the exception of
p53I132 which reproducibly produced significantly
higher levels of protein (Fig. 6 and data not shown).
Abrogation of p53 transcriptional activity by E6
The interaction between E6 and p53 has been shown
to lead to the inhibition of p53 transcriptional activity
(Crook et al., 1994; Mietz et al., 1992) and we therefore
assessed the effect of E6 expression on transactivation
by selected p53 mutants (Fig. 7). As expected, coexpres-
sion of E6 reduced the transcriptional activity of wild-
type p53 and p53D370, consistent with the ability of E6
to target these p53 proteins for degradation in the in vitro
system. Interestingly, the activity of p53I381/382/386 was
also equally efficiently abrogated by E6. Since this mutant
was resistant to E6-targeted degradation in vitro, these
results suggested the possibility that the binding of E6
to this p53 mutant was sufficient to interfere with trans-
activation. The amount of p53 protein present in each
cell lysate used to measure transcriptional activity was
therefore analyzed (Fig. 8A). These analyses clearly
showed that although the p53I381/382/386 protein is re-
sistant to E6-mediated degradation in vitro, in cells co-
expression of E6 results in the efficient degradation of
this protein. Comparison with the in vivo degradation of
p53 proteins which remain sensitive in the in vitro assay,
such as wild-type p53, p53D370, or p53I132, revealed FIG. 7. Sequence-specific transcriptional transactivation of pG13-luc
no significant difference in the sensitivity of the p53I381/ in p53 null mouse fibroblasts following transient transfection of 1.0 mg
of the indicated p53 plasmids and 0, 10, or 20 mg E6.382/386 protein. In contrast, the levels of expression of
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FIG. 8. (A) Western blot of extracts from p53 null mouse fibroblasts showing levels of p53 expression following transient transfection of 1.0 mg
of the indicated p53 plasmids and 0, 10, or 20 mg E6. In B, wild-type p53 and the p53DV mutant (lacking conserved box V) were expressed from
the CMV IE promoter (left) or the SV40 promoter used for all the other p53 proteins in this study (right).
effect on the ability of E6 to target degradation, but this activity of the whole protein and mutation, phosphoryla-
tion, or binding of the PAb421 antibody within this regionmutant did show some evidence of enhanced stability in
the absence of E6, a phenotype previously described for can augment sequence-specific DNA binding (Hupp and
Lane, 1994; Hupp et al., 1992; Jayaraman and Prives,p53 proteins mutated at residue 273 (Crook and Vous-
den, 1992; Scheffner et al., 1992b). Many transcriptionally 1995; Wang and Prives, 1995). Previous studies showed
that deletion of the C-terminal 30 amino acids or alterna-inactive tumor-derived mutant p53 proteins show en-
hanced stability and increased levels of protein expres- tively spliced forms of murine p53 resulting in loss of
the C-terminal 26 amino acids leads to the constitutivesion (Zambetti and Levine, 1993). Mutations at residue
132, as in p53I132, have been described in several hu- activation of DNA binding (Hupp et al., 1992; Wolkowicz
et al., 1995). We show here that truncation of the C-man cancers (Hollstein et al., 1994) and this mutant ap-
pears to have lost normal p53 function, such as se- terminal 24 amino acids of the human p53 protein in
p53D370 likewise confers constitutive DNA binding ac-quence-specific transcriptional activation, and so dis-
plays a phenotype similar to other tumor-derived point tivity. The triple mutation within p53I381/382/386 results
in loss of the PAb421 epitope, consistent with its locationmutants with alterations in the central conserved region
of the protein. Since many of these mutant p53s show within the C-terminal regulatory domain, although the
mutant protein did not show constitutive DNA-bindingenhanced stability, presumably as a consequence of
conformational alteration, it is not possible to assign a activity. However, an alteration within this regulatory re-
gion may contribute to the apparent resistance to degra-particular role for the lysine at residue 132 for ubiquitina-
tion. Indeed, the sensitivity of this mutant to E6-directed dation in vitro, despite allowing the interaction between
E6 and p53 to occur. The defect in E6-directed degrada-degradation suggests that this lysine is not absolutely
required for ubiquitin-directed proteolysis. Mutations of tion exhibited by p53I381/382/386 is clearly not mani-
fested in vivo, where the protein retains wild-type tran-the lysine at residue 139 have also been detected in
several human cancers, although the isoleucine substitu- scriptional activation, shows normal levels of expression
in transfected cells, and is targeted for degradation bytion in I139 did not appear to affect the functions of the
p53 protein studied here. Nevertheless, loss of transcrip- E6 as efficiently as the wild-type p53 protein. Study of
the in vitro interaction between E6 and p53 has giventional activity is not necessarily exhibited by tumor-asso-
ciated p53 mutants (Crook and Vousden, 1992) and loss rise to several contradictory reports (Crook et al., 1991b;
Foster et al., 1994; Lechner and Laimins, 1994; Scheffnerof activities such as the ability to induce apoptosis may
occur despite retention of transactivation function et al., 1992a), and there is no clear consensus on the
requirements for the E6/p53 interaction or the degrada-(Rowan et al., 1996).
Of particular interest is the behavior of the triple mutant tion of p53 by E6. Variation in the sensitivity of the in
vitro degradation assay used by various laboratories hasp53I381/382/386. In in vitro assays this mutant protein
shows resistance to E6-directed degradation, despite re- been noted (Crook et al., 1991b, 1994; Foster et al., 1994)
and the present study illustrates a further level of com-taining the ability to interact with the E6 protein. It seems
unlikely that the three lysines involved in this mutant are plexity to be considered, by demonstrating that the phe-
notype of a p53 mutant in the in vitro degradation assayspecifically targeted for ubiquitination, or that this region
is the binding site for the E6AP protein necessary for does not necessarily reflect the behavior of the same
protein when expressed in cells.degradation, because complete deletion of this region in
p53D370 generates a truncated protein which retains
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